Low percentage of aluminoxamine and ferroxamine in uremic serum after desferrioxamine administration

Clinical Chemistry

Volumn 44, Issue 6, 1998, Pages 1262-1268

  Menéndez Fraga, Pilar ^a   Fernández Martín, Jose L ^a   Blanco González, Elisa ^b   Cannata Andía, Jorge B ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRIOXAMINE;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CHELATION; CLINICAL ARTICLE; DRUG EFFECT; HEMODIALYSIS; HUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; ULTRAFILTRATION; UREMIA;

EID: 0031779169     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.6.1262     Document Type: Article

References (32)

1. Alfrey AC. Aluminium and renal disease. Contrib Nephrol 1993; 102:110-24.
2. Ackril P, Day JP. The use of desferrioxamine in dialysis-associated aluminium disease. Contrib Nephrol 1993;102:125-34.
3. Yokel RA. Aluminium chelation: chemistry, clinical and experimental studies and the search for alternatives to desferrioxamine. J Toxicol Environ Health 1994;41:131-74.
4. Trapp GA. Plasma aluminum is bound to transferrin. Life Sci 1983;33:311-6.
5. Rahman H, Skillen AW, Channon SM, Ward MK, Kerr DN. Methods for studying the binding of aluminum by serum protein. Clin Chem 1985;31:1969-73.
6. Garcia Alonso JI, López Garcia A, Pérez Parajón J, Blanco González E, Sanz Medel A, Cannata JB. High performance liquid chromatography methods for studying protein binding of aluminium in human serum in the absence and in the presence of desferrioxamine. Clin Chim Acta 1990;189:69-79.
7. Van Landeghem GF, D'Haese PC, Lamberts LV, De Broe ME. Quantitative HPLC/ETAAS hybrid method with an on-line metal scavenger for studying the protein binding and speciation of aluminium and iron. Anal Chem 1994;66:216-22.
8. Wrobel K, Blanco González E, Wrobel KZ, Sanz-Medel A. Aluminium and silicon speciation in human serum by ion-exchange high-performance liquid chromatography, electrothermal atomic absorption spectrometry and gel electrophoresis. Analyst 1995; 120:809-15.
9. 3+. Clin Chem 1987;33:405-7.
10. Keberle H. The biochemistry of desferrioxamine and his relation to iron metabolism. Ann N Y Acad Sci 1964;119:758-68.
11. Snow GA. Metal complexes of mycobactin P and of desferrisideramines. Biochem J 1969;115:199-205.
12. Moeschlin S, Schnider U. Treatment of primary and secondary hemochromatosis and acute iron poisoning with a new, potent iron eliminating agent (desferrioxamine-B). N Engl J Med 1963; 269:57-66.
13. Ackrill P, Ralston AJ, Day JP, Hodge KC. Successful removal of aluminium from patient with dialysis encephalopathy. Lancet 1980;2:692-3.
14. Douthat WG, Acuña Aguerre G, Fernández Martín JL, Mauzo R, Cannata Andía JB. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration. Nephrol Dial Transplant 1994;9:1431-4.
15. Canavese C, Gurioli L, D'Amicone M, Cardelli R, Caligaris F, Bongiorno P, et al. Kinetics of aluminoxamine and feroxamine chelates in dialysis patients. Nephron 1992;60:411-7.
16. Vasilakakis DM, D'Haese PC, Lamberts LV, Lemoniaton E, Digenis PN, De Broe ME. Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis. Kidney Int 1992; 41:1400-7.
17. Allain P, Chaleil D, Mauras Y, Beaudeau G, Varin MC, Poignet JL, et al. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis. Clin Chim Acta 1987;170:331-8.
18. Menéndez-Fraga P, Blanco-González E, Sanz-Medel A, Cannata-Andía JB. Micellar versus reversed phase liquid chromatography for the determination of desferrioxamine and its chelates with aluminium and iron in uremic serum. Talanta 1997;45:25-33.
19. Sanz Medel A, Rodríguez Roza R, González Alonso R, Noval Vallina A, Cannata JB. Atomic spectrometric methods (atomic absorption and inductively coupled plasma atomic emission) for the determination of aluminium at the parts per billion level in biological fluids. J Anal At Spectrom 1987;2:177-84.
20. Fernández-Martín JL, Menéndez-Fraga P, Canteros MA, Díaz-López JB, Cannata-Andía JB. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1). Clin Chim Acta 1994;230:137-45.
21. D'Haese PC, Lamberts LV, De Broe ME. Indirect measurement of desferrioxamine and its chelated compounds aluminoxamine and ferrioxamine by zeeman atomic absorption spectrometry. Clin Chem 1989;35:884-7.
22. Wrobel K, Blanco González E, Sanz Medel A. Ultrafilterable aluminum in normal and uremic serum: influence of desferrioxamine therapy. Trace Elem Med 1993;10:97-103.
23. Kruck TPA, Teichert-Kuliszewska K, Fisher E, Kalow W, MacLachlan DR. High-performance liquid chromatographic analysis of desferrioxamine. J Chromatogr 1988;433:207-16.
24. Sing S, Hider RC, Porter JB. Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: choice of complexing agent and application to biological fluids. Anal Biochem 1990;187:212-9.
25. Lehmann WD, Heinrich HC. Ferrioxamine and its hexadentate iron-chelating metabolites in human post-desferal urine studied by high-performance liquid chromatography and fast atom bombardment mass spectrometry. Anal Biochem 1990;184:219-27.
26. Khalil-Manesh F, Agness C, Gonick HC. Aluminum-binding protein in dialysis dementia. I. Characterization in plasma by gel chromatography and electrophoresis. Nephron 1989;52:323-8.
27. Khalil-Manesh F, Agness C, Gonick HC. Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration. Nephron 1989;52:329-33.
28. Favarato M, Mizzen CA, Sutherland MK, Krishnan B, Kruck TPA, Crapper McLachlan DR. Aluminum-binding serum proteins: desferrioxamine alters serum aluminum speciation. Clin Chim Acta 1992;207:41-55.
29. Lipschitz DA, Dugard J, Simon MO, Bothwell TH, Charlton RW. The site of action of desferrioxamine. Br J Haematol 1971;20:395-404.
30. Crichton RR, Roman F, Roland F. Ferritin iron mobilisation by chelating agents. FEBS Lett 1980;110:271-4.
31. Barata JD, D'Haese PC, Pires C, Lamberts LV, Simoes J, De Broe ME. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996;11:125-32.
32. Canteros A, Díaz-Corte C, Fernández-Martín JL, Gago E, Fernández-Merayo C, Cannata JB. Ultrafilterable aluminium after very low doses of desferrioxamine. Nephrol Dial Transplant 1998;(in press).